VYNE shares rise 13.19% after-hours as Q3 loss beats estimates and revenue tops forecasts, with strategic review underway to boost shareholder value.

VYNE Therapeutics Inc. surged 13.19% in after-hours trading following the release of better-than-expected Q3 financial results and strategic updates. The company reported a $0.17-per-share loss, surpassing the $0.19 consensus estimate, while revenue of $0.17 million exceeded estimates by 12.67%. Management highlighted cost reductions extending the cash runway into mid-2027 and initiated a strategic review to evaluate partnerships, asset sales, or other value-creating alternatives. Additionally, a 12-week non-clinical toxicology study for VYN202 was launched to address an FDA partial hold on male clinical trials, signaling progress in resolving regulatory hurdles. These developments—combined with a 39.7% year-over-year revenue increase and reduced net loss—boosted investor confidence, driving the post-earnings rally.